Cas:1731-81-3 Undecyl acetate manufacturer & supplier

Chemical Name:Undecyl acetate

CAS.NO:1731-81-3

Synonyms:1-Undecanol, acetate;n-Undecyl acetate;Undecyl acetate;1-Undecanol,1-acetate;EINECS 217-051-1;1-Undecanol,acetate

Molecular Formula:C₁₃H₂₆O₂

Molecular Weight:214.344

HS Code:2915390090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:259.4±3.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.433

PSA:26.30000

Exact Mass:214.193283

LogP:5.49

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-Undecanol, acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Undecanol,acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Undecanol,acetate Use and application,Undecyl acetate technical grade,usp/ep/jp grade.

Related News: The U.K. government previously purchased more than 380 million rapid tests from Innova, to help set up programs capable of screening millions of people per day—in the run-up to offering free COVID-19 testing nationwide at least twice per week. Undecyl acetate manufacturer If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. Undecyl acetate supplier If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. Undecyl acetate vendor The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. Undecyl acetate factory If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said.